From Surf Wiki (app.surf) — the open knowledge base
2-Oxo-3-hydroxy-LSD
| Column 1 |
|---|
| 2-Oxy-3-hydroxy-LSD; OH-LSD; O-H-LSD; 2-Oxo-3-OH-LSD; 2-Oxo-3-hydroxy-2,3-dihydro-LSD; 2-Oxo-3-hydroxylysergide; 2-Oxo-3-hydroxylysergic acid diethylamide; N,N-Diethyl-2,3-dihydro-2-oxo-3-hydroxylysergamide; N,N-Diethyl-3-hydroxy-6-methyl-2-oxo-9,10-didehydro-2,3-dihydroergoline-8β-carboxamide |
| Serotonin receptor modulator |
| .mw-parser-output .plainlist ol,.mw-parser-output .plainlist ul{line-height:inherit;list-style:none;margin:0;padding:0}.mw-parser-output .plainlist ol li,.mw-parser-output .plainlist ul li{margin-bottom:0}None |
| IUPAC name |
| (6aR,9R)-N,N-diethyl-5a-hydroxy-7-methyl-5-oxo-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide |
| 111295-09-1 |
| 10155149 |
| 8330657 |
| KU55DR6345 |
| DTXSID00436244 |
| C20H25N3O3 |
| 355.438 g·mol−1 |
| Interactive image |
| SMILES |
| CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3(C4=C(C2=C1)C=CC=C4NC3=O)O)C |
| InChI |
| InChI=1S/C20H25N3O3/c1-4-23(5-2)18(24)12-9-14-13-7-6-8-15-17(13)20(26,19(25)21-15)10-16(14)22(3)11-12/h6-9,12,16,26H,4-5,10-11H2,1-3H3,(H,21,25)/t12-,16-,20?/m1/s1Key:YSZSHHCNLVHCNV-VRORWYBRSA-N |
2-Oxo-3-hydroxy-LSD, or 2-oxy-3-hydroxy-LSD, also known as O-H-LSD or OH-LSD, as well as more fully as 2-oxo-3-hydroxy-2,3-dihydro-LSD, is a lysergamide and the major metabolite of the psychedelic drug lysergic acid diethylamide (LSD). LSD is eliminated 13% as O-H-LSD in urine within 24 hours and urinary concentrations of O-H-LSD are 4 to 40 times those of LSD in humans.
The specific enzymes responsible for the formation of O-H-LSD from LSD are unclear. However, subsequent research found involvement of several cytochrome P450 enzymes. O-H-LSD is thought to form from other LSD metabolites like 2-oxo-LSD and 3-hydroxy-LSD.
It is unknown whether O-H-LSD is pharmacologically active or produces hallucinogenic effects. However, O-H-LSD showed profoundly reduced albeit still detectable activity at the serotonin 5-HT2 receptors, including the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, compared to LSD in vitro.
O-H-LSD was first described in the scientific literature by at least the 1990s. It started being sold online as an analytical standard by 2024.
-
Substituted lysergamide
-
2-Oxo-LSD
-
2,3-Dihydro-LSD
-
Nor-LSD
-
Lysergic acid ethyl-2-hydroxyethylamide (LEO)
-
Lysergic acid ethylamide (LAE)
-
13-Hydroxy-LSD
-
14-Hydroxy-LSD
-
OH-LSD - Isomer Design
Ask Mako anything about 2-Oxo-3-hydroxy-LSD — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report